All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
7th European CAR T-cell Meeting congress coverage
Bookmark this article
Stay up to date with the latest developments in acute lymphoblastic leukemia with our live social media coverage from the 7th European CAR T-cell Meeting, February 6–8, 2025, Strasbourg, France
CONGRESS | #CART25 | PRESENTATION
— ALL Hub (@ALL_Hub_) February 6, 2025
Peter Bader, @goetheuni discusses key data from real-world studies of tisagenlecleucel in pediatric patients with ALL. Results suggest that disease burden and early relapses post allo-HSCT impact survival outcomes.#leusm #ALLsm #MedicalCongress pic.twitter.com/xhpQUEQ7yW
CONGRESS | #CART25 | PRESENTATION@drclaireroddie @ucl @uclcancer @uclh discusses CAR T-cell therapies for adult patients with ALL. They highlight results from the FELIX trial of obe-cel in adult patients with R/R B-ALL, and discuss factors associated with survival outcomes.… pic.twitter.com/s80eOKm6gB
— ALL Hub (@ALL_Hub_) February 6, 2025
CONGRESS | #CART25 | PRESENTATION
— ALL Hub (@ALL_Hub_) February 8, 2025
Valentin Ortiz-Maldonado @ValentinOrtizMD @hospitalclinic presents initial results from the CART19-BE-02 trial of varnimcabtagene autoleucel in adult patients with R/R B-ALL. The primary endpoint was met, with an MRD-negative CR rate at Day +28… pic.twitter.com/fkbJAX7KG8
Your opinion matters
21 votes - 86 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox